BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaneku H, O'Leary JG, Banuelos N, Jennings LW, Susskind BM, Klintmalm GB, Terasaki PI. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013;13:1541-8. [PMID: 23721554 DOI: 10.1002/ajt.12212] [Cited by in Crossref: 175] [Cited by in F6Publishing: 108] [Article Influence: 19.4] [Reference Citation Analysis]
Number Citing Articles
1 Cillo U, Bechstein WO, Berlakovich G, Dutkowski P, Lehner F, Nadalin S, Saliba F, Schlitt HJ, Pratschke J. Identifying risk profiles in liver transplant candidates and implications for induction immunosuppression. Transplantation Reviews 2018;32:142-50. [DOI: 10.1016/j.trre.2018.04.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Kubal CA, Mangus R, Ekser B, Mihaylov P, Ceballos B, Higgins N, Chalasani N, Ghabril M, Nephew L, Lobashevsky A. Class II Human Leukocyte Antigen Epitope Mismatch Predicts De Novo Donor-Specific Antibody Formation After Liver Transplantation. Liver Transpl 2018;24:1101-8. [PMID: 30142248 DOI: 10.1002/lt.25286] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
3 Neil DA, Bellamy CO, Smith M, Haga H, Zen Y, Sebagh M, Ruppert K, Lunz J, Hübscher SG, Demetris AJ. Global quality assessment of liver allograft C4d staining during acute antibody-mediated rejection in formalin-fixed, paraffin-embedded tissue. Human Pathology 2018;73:144-55. [DOI: 10.1016/j.humpath.2017.12.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
4 Tokodai K, Miyagi S, Nakanishi W, Fujio A, Kashiwadate T, Goto M, Unno M, Kamei T. Effects of re-augmenting maintenance immunosuppression on post-transplant donor-specific HLA antibodies in liver transplantation. Transpl Immunol 2020;63:101334. [PMID: 32919028 DOI: 10.1016/j.trim.2020.101334] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 O'Leary JG, Philippe A, Freeman R, Heidecke H, Jennings LW, Catar R, Klintmalm GB, Dragun D. Non-HLA Autoantibodies at 1 Year Negatively Affect 5-Year Native Renal Function in Liver Transplant Recipients. Transplant Proc 2021;53:1019-24. [PMID: 33579550 DOI: 10.1016/j.transproceed.2021.01.013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Burghuber C, Roberts T, Knechtle S. The clinical relevance of alloantibody in liver transplantation. Transplantation Reviews 2015;29:16-22. [DOI: 10.1016/j.trre.2014.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Mallon DH, Bradley JA, Taylor CJ, Kosmoliaptsis V. Structural and electrostatic analysis of HLA B-cell epitopes: inference on immunogenicity and prediction of humoral alloresponses. Curr Opin Organ Transplant 2014;19:420-7. [PMID: 24977436 DOI: 10.1097/MOT.0000000000000108] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 3.1] [Reference Citation Analysis]
8 Feng S, Bucuvalas J. Tolerance after liver transplantation: Where are we? Liver Transpl. 2017;23:1601-1614. [PMID: 28834221 DOI: 10.1002/lt.24845] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
9 . Harald C. Ott: Clinician-scientist, Cardiothoracic Surgeon, Massachusetts General Hospital, Harvard Medical School. Transplantation 2019;103:862-3. [DOI: 10.1097/tp.0000000000002339] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Mittal S, Page SL, Friend PJ, Sharples EJ, Fuggle SV. De novo donor-specific HLA antibodies: biomarkers of pancreas transplant failure. Am J Transplant 2014;14:1664-71. [PMID: 24866735 DOI: 10.1111/ajt.12750] [Cited by in Crossref: 55] [Cited by in F6Publishing: 37] [Article Influence: 6.9] [Reference Citation Analysis]
11 Shapiro AM. Donor-specific Antibody in Pediatric Liver Transplantation-Identifying a Tree by Its Fruit. Transplantation 2015;99:1314-5. [PMID: 26038875 DOI: 10.1097/TP.0000000000000795] [Reference Citation Analysis]
12 Ascha MS, Ascha ML, Hanouneh IA. Management of immunosuppressant agents following liver transplantation: Less is more. World J Hepatol 2016; 8(3): 148-161 [PMID: 26839639 DOI: 10.4254/wjh.v8.i3.148] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
13 Charlton M, Levitsky J, Aqel B, OʼGrady J, Hemibach J, Rinella M, Fung J, Ghabril M, Thomason R, Burra P, Little EC, Berenguer M, Shaked A, Trotter J, Roberts J, Rodriguez-Davalos M, Rela M, Pomfret E, Heyrend C, Gallegos-Orozco J, Saliba F. International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation 2018;102:727-43. [PMID: 29485508 DOI: 10.1097/TP.0000000000002147] [Cited by in Crossref: 61] [Cited by in F6Publishing: 22] [Article Influence: 20.3] [Reference Citation Analysis]
14 Vionnet J, Sempoux C, Pascual M, Sánchez-fueyo A, Colmenero J. Donor-specific antibodies in liver transplantation. Gastroenterología y Hepatología 2020;43:34-45. [DOI: 10.1016/j.gastrohep.2019.09.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
15 Iacob S, Cicinnati VR, Lindemann M, Heinemann FM, Radtke A, Kaiser GM, Kabar I, Schmidt HH, Baba HA, Beckebaum S. Donor-Specific Anti-HLA Antibodies and Endothelial C4d Deposition-Association With Chronic Liver Allograft Failure. Transplantation 2015;99:1869-75. [PMID: 25706274 DOI: 10.1097/TP.0000000000000613] [Cited by in Crossref: 30] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
16 Kim PT, Demetris AJ, O'Leary JG. Prevention and treatment of liver allograft antibody-mediated rejection and the role of the 'two-hit hypothesis'. Curr Opin Organ Transplant 2016;21:209-18. [PMID: 26918881 DOI: 10.1097/MOT.0000000000000275] [Cited by in Crossref: 39] [Cited by in F6Publishing: 3] [Article Influence: 6.5] [Reference Citation Analysis]
17 Luo Y, Ji W, Duan W, Ye S, Dong J. Graft cholangiopathy: etiology, diagnosis, and therapeutic strategies. Hepatobiliary & Pancreatic Diseases International 2014;13:10-7. [DOI: 10.1016/s1499-3872(14)60001-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
18 Karahan GE, Vaal YJH, Krop J, Wehmeier C, Roelen DL, Claas FHJ, Heidt S. A Memory B Cell Crossmatch Assay for Quantification of Donor‐Specific Memory B Cells in the Peripheral Blood of HLA ‐Immunized Individuals. Am J Transplant 2017;17:2617-26. [DOI: 10.1111/ajt.14293] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
19 Zhou S, Mitsinikos T, Emamaullee J, Weaver C, Wang L, Shillingford N, Warren M, Bawab JH, Tiwari N, Genyk Y, Thomas D, Parham DM. Clinicopathologic Characteristics of Late Acute Antibody-mediated Rejection in Pediatric Liver Transplantation. Transplantation 2021;105:2045-53. [PMID: 33031223 DOI: 10.1097/TP.0000000000003469] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Vandermeulen M, Mohamed-Wais M, Erpicum P, Delbouille MH, Lechanteur C, Briquet A, Maggipinto G, Jouret F, Beguin Y, Detry O. Infusion of Allogeneic Mesenchymal Stromal Cells After Liver Transplantation: A 5-Year Follow-Up. Liver Transpl 2021. [PMID: 34605167 DOI: 10.1002/lt.26323] [Reference Citation Analysis]
21 Chen G, Lin L, Tyan DB. DSA-FXM: Accelerated Donor-specific Flow Crossmatch Discriminating Class I and II Antibody Specifically and Only to Donor HLA for Determining True Incompatibility. Transplantation 2020;104:813-22. [PMID: 31385929 DOI: 10.1097/TP.0000000000002900] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Timofeeva OA. Donor-Specific HLA Antibodies as Biomarkers of Transplant Rejection. Clinics in Laboratory Medicine 2019;39:45-60. [DOI: 10.1016/j.cll.2018.10.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
23 Malheiro J, Martins LS, Tafulo S, Dias L, Fonseca I, Beirão I, Castro-henriques A, Cabrita A. Impact of de novo donor-specific anti-HLA antibodies on grafts outcomes in simultaneous pancreas-kidney transplantation. Transpl Int 2016;29:173-83. [DOI: 10.1111/tri.12687] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
24 Ducreux S, Guillaud O, Bosch A, Thaunat O, Morelon E, Hervieu V, Mekki Y, Boillot O, Scoazec J, Dubois V, Dumortier J. Monitoring efficiency of humoral rejection episode therapy in liver transplantation: any role for complement binding Luminex Single Antigen assays? Transplant Immunology 2016;35:23-8. [DOI: 10.1016/j.trim.2016.01.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
25 Del Bello A, Congy-Jolivet N, Muscari F, Lavayssière L, Esposito L, Cardeau-Desangles I, Guitard J, Dörr G, Suc B, Duffas JP, Alric L, Bureau C, Danjoux M, Guilbeau-Frugier C, Blancher A, Rostaing L, Kamar N. Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients. Am J Transplant 2014;14:867-75. [PMID: 24580771 DOI: 10.1111/ajt.12651] [Cited by in Crossref: 79] [Cited by in F6Publishing: 66] [Article Influence: 9.9] [Reference Citation Analysis]
26 Crespo M, Heidt S, Redondo D, Pascual J. Monitoring B cell subsets and alloreactivity in kidney transplantation. Transplant Rev (Orlando) 2015;29:45-52. [PMID: 25867605 DOI: 10.1016/j.trre.2015.02.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
27 Tambur AR. HLA-DQ antibodies: are they real? Are they relevant? Why so many? Curr Opin Organ Transplant 2016;21:441-6. [PMID: 27200497 DOI: 10.1097/MOT.0000000000000325] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
28 O'Leary JG. Donor-specific alloantibodies in liver transplantation: how should we define and improve long-term success? Transpl Int 2015;28:1359-61. [PMID: 26284821 DOI: 10.1111/tri.12661] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Everly MJ, Roberts M, Townsend R, Bray RA, Gebel HM. Comparison of de novo IgM and IgG anti-HLA DSAs between belatacept- and calcineurin-treated patients: An analysis of the BENEFIT and BENEFIT-EXT trial cohorts. Am J Transplant 2018;18:2305-13. [DOI: 10.1111/ajt.14939] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
30 O'leary JG, Demetris AJ, Philippe A, Freeman R, Cai J, Heidecke H, Smith C, Hart B, Jennings LW, Catar R, Everly M, Klintmalm GB, Dragun D. Non-HLA Antibodies Impact on C4d Staining, Stellate Cell Activation and Fibrosis in Liver Allografts. Transplantation 2017;101:2399-409. [DOI: 10.1097/tp.0000000000001853] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 4.8] [Reference Citation Analysis]
31 Demetris AJ, Bellamy CO, Gandhi CR, Prost S, Nakanuma Y, Stolz DB. Functional Immune Anatomy of the Liver-As an Allograft. Am J Transplant. 2016;16:1653-1680. [PMID: 26848550 DOI: 10.1111/ajt.13749] [Cited by in Crossref: 50] [Cited by in F6Publishing: 37] [Article Influence: 8.3] [Reference Citation Analysis]
32 Dao M, Habès D, Taupin JL, Mussini C, Redon MJ, Suberbielle C, Jacquemin E, Gonzales E, Guettier C. Morphological characterization of chronic antibody-mediated rejection in ABO-identical or ABO-compatible pediatric liver graft recipients. Liver Transpl 2018;24:897-907. [PMID: 29704327 DOI: 10.1002/lt.25187] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
33 Goria O, Archambeaud I, Lemaitre C, Dutheil D, Plessier A, Rautou PE, Hernandez-Gea V, Valla D. Ischemic cholangiopathy: An update. Clin Res Hepatol Gastroenterol 2020;44:486-90. [PMID: 32461060 DOI: 10.1016/j.clinre.2020.03.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Matsumoto CS, Rosen-Bronson S. Donor-specific antibody and sensitized patients in intestinal transplantation. Curr Opin Organ Transplant 2021;26:245-9. [PMID: 33528224 DOI: 10.1097/MOT.0000000000000853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Willuweit K, Heinold A, Rashidi-alavijeh J, Heinemann FM, Horn PA, Paul A, Gerken G, Herzer K. Immunosuppression with mTOR inhibitors prevents the development of donor-specific antibodies after liver transplant. Clin Transplant 2017;31:e12974. [DOI: 10.1111/ctr.12974] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
36 Kohut TJ, Barandiaran JF, Keating BJ. Genomics and Liver Transplantation: Genomic Biomarkers for the Diagnosis of Acute Cellular Rejection. Liver Transpl 2020;26:1337-50. [DOI: 10.1002/lt.25812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Couchonnal E, Rivet C, Ducreux S, Dumortier J, Bosch A, Boillot O, Collardeau-Frachon S, Dubois R, Hervieu V, André P, Scoazec JY, Lachaux A, Dubois V, Guillaud O. Deleterious impact of C3d-binding donor-specific anti-HLA antibodies after pediatric liver transplantation. Transpl Immunol 2017;45:8-14. [PMID: 28782692 DOI: 10.1016/j.trim.2017.08.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
38 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Kamar N. Donor-specific antibodies and liver transplantation. Hum Immunol. 2016; Feb 23. [Epub ahead of print]. [PMID: 26916836 DOI: 10.1016/j.humimm.2016.02.006] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 5.7] [Reference Citation Analysis]
39 Kovandova B, Slavcev A, Sekerkova Z, Honsova E, Trunecka P. Antibody-mediated rejection after liver transplantation-relevance of C1q and C3d-binding antibodies. HLA 2018;92:34-7. [DOI: 10.1111/tan.13354] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
40 Leino AD, Pai MP. Maintenance Immunosuppression in Solid Organ Transplantation: Integrating Novel Pharmacodynamic Biomarkers to Inform Calcineurin Inhibitor Dose Selection. Clin Pharmacokinet 2020;59:1317-34. [PMID: 32720300 DOI: 10.1007/s40262-020-00923-w] [Reference Citation Analysis]
41 Parajuli S, Joachim E, Alagusundaramoorthy S, Blazel J, Aziz F, Garg N, Muth B, Mohamed M, Mandelbrot D, Zhong W, Djamali A. Subclinical Antibody-mediated Rejection After Kidney Transplantation: Treatment Outcomes. Transplantation 2019;103:1722-9. [DOI: 10.1097/tp.0000000000002566] [Cited by in Crossref: 33] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
42 Iwasaki K, Miwa Y, Uchida K, Kodera Y, Kobayashi T. Negative regulation of HLA-DR expression on endothelial cells by anti-blood group A/B antibody ligation and mTOR inhibition. Transpl Immunol 2017;40:22-30. [PMID: 28017877 DOI: 10.1016/j.trim.2016.12.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
43 Zimmerman MA, Schiller J, Kim J, Martin A, Selim M, Nydam TL, Cronin D 2nd, Hong JC. Pathologic sequelae of allosensitization in liver transplantation. J Surg Res 2016;200:195-9. [PMID: 26253457 DOI: 10.1016/j.jss.2015.06.047] [Reference Citation Analysis]
44 Suhling H, Gottlieb J, Bara C, Taubert R, Jäckel E, Schiffer M, Bräsen J. Chronische Abstoßung: Unterschiede und Ähnlichkeiten bei verschiedenen soliden Organtransplantationen. Internist 2016;57:25-37. [DOI: 10.1007/s00108-015-3806-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
45 O'Leary JG, Kaneku H, Banuelos N, Jennings LW, Klintmalm GB, Terasaki PI. Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation. Am J Transplant 2015;15:1003-13. [PMID: 25772599 DOI: 10.1111/ajt.13153] [Cited by in Crossref: 99] [Cited by in F6Publishing: 87] [Article Influence: 14.1] [Reference Citation Analysis]
46 Vellalta G, Dopazo C, Bilbao I, Castells L, Sapisochin G, Lázaro J, Montero Á, Salcedo M, Caralt M, Charco R. Acute Antibody-Mediated Rejection as Cause of Late Liver Allograft Failure: A Case Report. Transplantation Proceedings 2015;47:3016-9. [DOI: 10.1016/j.transproceed.2015.10.036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Del Bello A, Danjoux M, Congy-jolivet N, Lavayssière L, Esposito L, Muscari F, Kamar N. Histological long-term outcomes from acute antibody-mediated rejection following ABO-compatible liver transplantation: Outcome of antibody mediated rejection. Journal of Gastroenterology and Hepatology 2017;32:887-93. [DOI: 10.1111/jgh.13613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
48 Londoño MC, Souza LN, Lozano JJ, Miquel R, Abraldes JG, Llovet LP, Quaglia A, Rimola A, Navasa M, Sánchez-Fueyo A. Molecular profiling of subclinical inflammatory lesions in long-term surviving adult liver transplant recipients. J Hepatol 2018;69:626-34. [PMID: 29709679 DOI: 10.1016/j.jhep.2018.04.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
49 Schluckebier D, Cousin VL, Petit L, Belli D, Wildhaber B, Rougemont A, Villard J, Ferrari‐lacraz S, Mclin VA. Preformed and de novo DSA are associated with T‐cell–mediated rejection in pediatric liver transplant recipients requiring clinically indicated liver biopsy. Pediatr Transplant 2020;24. [DOI: 10.1111/petr.13611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
50 Ibáñez-samaniego L, Salcedo M, Vaquero J, Bañares R. De novo autoimmune hepatitis after liver transplantation: A focus on glutathione S-transferase theta 1: ibáñez-Samaniego et al. Liver Transpl 2017;23:75-85. [DOI: 10.1002/lt.24652] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
51 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol 2018; 24(16): 1795-1802 [PMID: 29713132 DOI: 10.3748/wjg.v24.i16.1795] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
52 Jambon F, Merville P, Guidicelli G, Taton B, De Précigout V, Couzi L, Moreau K, Visentin J. Efficacy of plasmapheresis and semi-selective immunoadsorption for removal of anti-HLA antibodies. J Clin Apher 2021;36:291-8. [PMID: 33253430 DOI: 10.1002/jca.21858] [Reference Citation Analysis]
53 Sakamoto S, Akamatsu N, Hasegawa K, Ohdan H, Nakagawa K, Egawa H. The efficacy of rituximab treatment for antibody-mediated rejection in liver transplantation: A retrospective Japanese nationwide study. Hepatol Res 2021;51:990-9. [PMID: 33818877 DOI: 10.1111/hepr.13643] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
54 Taner T, Stegall MD, Heimbach JK. Antibody-mediated rejection in liver transplantation: current controversies and future directions. Liver Transpl 2014;20:514-27. [PMID: 24470340 DOI: 10.1002/lt.23826] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
55 Sultani B, Marget M, Briem-Richter A, Herrmann J, Meisner S, Grabhorn EF, Ozga AK, Weidemann S, Herden U, Fischer L, Sterneck M. Presence of donor specific HLA class 2 antibodies (DSA class 2) is associated with development of graft fibrosis more than 10 years after liver transplantation-a retrospective single center study. Clin Transplant 2021;35:e14336. [PMID: 33949011 DOI: 10.1111/ctr.14336] [Reference Citation Analysis]
56 Kornberg A. Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation. World J Hepatol 2015; 7(11): 1494-1508 [PMID: 26085909 DOI: 10.4254/wjh.v7.i11.1494] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
57 Arias M, Rush DN, Wiebe C, Gibson IW, Blydt-Hansen TD, Nickerson PW, Sellarés J, López-Hoyos M, San Segundo D, Crespo-Leiro MG, Marzoa-Rivas R, Barge-Caballero E, Paniagua-Martín MJ, Román A, Serón D, Böhmig G, Schwaiger E. Antibody-mediated rejection: analyzing the risk, proposing solutions. Transplantation 2014;98 Suppl 3:S3-21. [PMID: 25093441 DOI: 10.1097/TP.0000000000000218] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
58 Hiramitsu T, Tomosugi T, Futamura K, Okada M, Nishihira M, Goto N, Ichimori T, Narumi S, Kobayashi T, Uchida K, Watarai Y. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study. Int Immunopharmacol 2021;91:107038. [PMID: 33388731 DOI: 10.1016/j.intimp.2020.107038] [Reference Citation Analysis]
59 Neau-cransac M, Le Bail B, Guidicelli G, Visentin J, Moreau K, Quinart A, Boueilh A, Laurent C, Taupin J. Evolution of serum and intra-graft donor-specific anti-HLA antibodies in a patient with two consecutive liver transplantations. Transplant Immunology 2015;33:58-62. [DOI: 10.1016/j.trim.2015.08.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
60 Eckels DD, Stehlik J, Kfoury AG. The detection and role of circulating antibodies in rejection: . Current Opinion in Organ Transplantation 2013;18:589-94. [DOI: 10.1097/mot.0b013e328364fe3d] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
61 den Dulk AC, Shi X, Verhoeven CJ, Dubbeld J, Claas FHJ, Wolterbeek R, Brand-schaaf SH, Verspaget HW, Sarasqueta AF, van der Laan LJW, Metselaar HJ, van Hoek B, Kwekkeboom J, Roelen DL. Donor-specific anti-HLA antibodies are not associated with nonanastomotic biliary strictures but both are independent risk factors for graft loss after liver transplantation. Clin Transplant 2018;32:e13163. [DOI: 10.1111/ctr.13163] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
62 Papachristou M, Fylaktou A, Daoudaki M, Cholongitas E, Karampatakis T, Anastasiou A, Chatzika G, Makrovasili F, Vagiotas L, Karakasi K, Fouzas I. Prevalence and Impact of Reformed and De Novo Anti-HLA Donor-Specific Antibodies in Liver Transplantation. Transplant Proc 2019;51:424-8. [PMID: 30879557 DOI: 10.1016/j.transproceed.2019.01.074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 San Segundo D, Alonso C, Ruiz P, Romon I, Arias-Loste MT, Cuadrado A, Puente A, Casafont F, López-Hoyos M, Crespo J, Fábrega E. De Novo Donor-Specific Anti-Human Leukocyte Antigen Antibody Detection in Long-Term Adult Liver Transplantation. Transplant Proc 2016;48:2980-2. [PMID: 27932124 DOI: 10.1016/j.transproceed.2016.08.037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
64 Kim SC, Foley DP. Donor-specific antibodies in liver transplantation: challenges in diagnosis and determining clinical impact. Curr Opin Organ Transplant 2020;25:549-54. [PMID: 33105198 DOI: 10.1097/MOT.0000000000000825] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Côté JM, Zhang X, Dahhou M, Sapir-Pichhadze R, Foster B, Cardinal H. The impact of repeated mismatches in kidney transplantations performed after nonrenal solid organ transplantation. Am J Transplant 2018;18:238-44. [PMID: 28891113 DOI: 10.1111/ajt.14495] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
66 Yamada Y, Hoshino K, Mori T, Kawaida M, Abe K, Ishihama H, Shimizu T, Takahashi N, Matsubara K, Hibi T, Abe Y, Yagi H, Shimojima N, Shinoda M, Kitago M, Obara H, Fuchimoto Y, Kameyama K, Kitagawa Y, Kuroda T. Successful living donor liver retransplantation for graft failure within 7 days due to acute de novo donor-specific anti-human leukocyte antigen antibody-mediated rejection: Re-LTx for graft failure secondary to de novo AMR. Hepatol Res 2018;48:E360-6. [DOI: 10.1111/hepr.12924] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
67 Lee M. Antibody-Mediated Rejection After Liver Transplant. Gastroenterology Clinics of North America 2017;46:297-309. [DOI: 10.1016/j.gtc.2017.01.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
68 Kim MH, Akbari O, Genyk Y, Kohli R, Emamaullee J. Immunologic benefit of maternal donors in pediatric living donor liver transplantation. Pediatr Transplant 2019;23:e13560. [PMID: 31402535 DOI: 10.1111/petr.13560] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
69 Levitsky J, Feng S. Tolerance in clinical liver transplantation. Hum Immunol. 2018;79:283-287. [PMID: 29054397 DOI: 10.1016/j.humimm.2017.10.007] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 9.4] [Reference Citation Analysis]
70 Salvadori M, Bertoni E. What’s new in clinical solid organ transplantation by 2013. World J Transplant 2014; 4(4): 243-266 [PMID: 25540734 DOI: 10.5500/wjt.v4.i4.243] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
71 Cuervo Florez M, Bruner J, Zarrinpar A. Progress and challenges in diagnosis and treatment of rejection following liver transplantation. Curr Opin Organ Transplant 2021;26:669-74. [PMID: 34581291 DOI: 10.1097/MOT.0000000000000924] [Reference Citation Analysis]
72 O'Leary JG, Smith C, Cai J, Hart B, Jennings LW, Everly M, Klintmalm GB, Demetris AJ. Chronic AMR in Liver Transplant: Validation of the 1-Year cAMR Score's Ability to Determine Long-term Outcome. Transplantation 2017;101:2062-70. [PMID: 28452922 DOI: 10.1097/TP.0000000000001802] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
73 Tambur AR, Kosmoliaptsis V, Claas FHJ, Mannon RB, Nickerson P, Naesens M. Significance of HLA-DQ in kidney transplantation: time to reevaluate human leukocyte antigen matching priorities to improve transplant outcomes? An expert review and recommendations. Kidney Int 2021:S0085-2538(21)00657-8. [PMID: 34246656 DOI: 10.1016/j.kint.2021.06.026] [Reference Citation Analysis]
74 Mehra NK, Baranwal AK. Clinical and immunological relevance of antibodies in solid organ transplantation. Int J Immunogenet 2016;43:351-68. [DOI: 10.1111/iji.12294] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
75 Jucaud V, Shaked A, DesMarais M, Sayre P, Feng S, Levitsky J, Everly MJ. Prevalence and Impact of De Novo Donor-Specific Antibodies During a Multicenter Immunosuppression Withdrawal Trial in Adult Liver Transplant Recipients. Hepatology. 2019;69:1273-1286. [PMID: 30229989 DOI: 10.1002/hep.30281] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
76 Ali MA, Elshobari MM, Salah T, Kandeel AR, Sultan AM, Elghawalby AN, Shehta A, Elsayed U, Fathy O, Yassen A, Wahab MA. Impact of donor-recipient genetic relationship on outcome of living donor liver transplantation. Liver Transpl 2017;23:43-9. [PMID: 27516392 DOI: 10.1002/lt.24599] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
77 De Martin E, Hessheimer A, Chadha R, Kabacam G, Rajanayagam J, Kirchner V, Kalisvaart M, Scalera I, Bhat M, Contreras A, Bhangui P. Report of the 24th Annual Congress of the International Liver Transplantation Society. Transplantation 2019;103:465-9. [DOI: 10.1097/tp.0000000000002549] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
78 Zhang H, Fu Q, Zheng Y, Li J, Wang S, Deng R, Huang G, Deng W, Huang H, Liu L, Wang C. Effect of Early Immunosuppression Therapy on De Novo Anti-Human-Leukocyte-Antigen Antibody After Kidney Transplantation. Transplant Proc 2018;50:2382-7. [PMID: 30316362 DOI: 10.1016/j.transproceed.2018.03.043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
79 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Cardeau-Desangles I, Guitard J, Dörr G, Milongo D, Suc B, Duffas JP, Alric L, Bureau C, Guilbeau-Frugier C, Rostaing L, Kamar N. De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients. Transpl Int. 2015;28:1371-1382. [PMID: 26303035 DOI: 10.1111/tri.12654] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 9.0] [Reference Citation Analysis]
80 Hirai T, Furusawa M, Omoto K, Ishida H, Tanabe K. Analysis of Predictive and Preventive Factors for De Novo DSA in Kidney Transplant Recipients. Transplantation 2014;98:443-50. [DOI: 10.1097/tp.0000000000000071] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 3.1] [Reference Citation Analysis]
81 Del Bello A, Congy-Jolivet N, Rostaing L, Kamar N. Incidence of anti-HLA donor specific antibodies in liver-transplant patients given mTOR inhibitors without calcineurin inhibitors. J Hepatol 2014;61:963-5. [PMID: 24999017 DOI: 10.1016/j.jhep.2014.06.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
82 Oniscu GC, Diaz G, Levitsky J. Meeting report of the 19th Annual International Congress of the International Liver Transplantation Society (Sydney Convention and Exhibition Centre, Sydney, Australia, June 12-15, 2013). Liver Transpl 2014;20:7-14. [PMID: 24136728 DOI: 10.1002/lt.23767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
83 Mendoza Rojas A, Hesselink DA, van Besouw NM, Baan CC, van Gelder T. Impact of low tacrolimus exposure and high tacrolimus intra-patient variability on the development of de novo anti-HLA donor-specific antibodies in kidney transplant recipients. Expert Rev Clin Immunol 2019;15:1323-31. [PMID: 31721605 DOI: 10.1080/1744666X.2020.1693263] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
84 O'Leary JG, Kaneku H, Jennings L, Susskind BM, Terasaki PI, Klintmalm GB. Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients. Liver Transpl 2014;20:655-63. [PMID: 24678017 DOI: 10.1002/lt.23854] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
85 Gebel HM, Bray RA. A diagnostic ‘C’ saw: the ups and downs of C1q testing. Current Opinion in Organ Transplantation 2019;24:402-10. [DOI: 10.1097/mot.0000000000000659] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
86 Hogen R, DiNorcia J, Dhanireddy K. Antibody-mediated rejection: what is the clinical relevance? Curr Opin Organ Transplant 2017;22:97-104. [PMID: 28060025 DOI: 10.1097/MOT.0000000000000391] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
87 Schlickeiser S, Boës D, Streitz M, Sawitzki B. The use of novel diagnostics to individualize immunosuppression following transplantation. Transpl Int 2015;28:911-20. [PMID: 25611562 DOI: 10.1111/tri.12527] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
88 Parajuli S, Aziz F, Blazel J, Muth BL, Garg N, Mohamed M, Rice J, Mezrich JD, Hidalgo LG, Mandelbrot D. The Utility of Donor-specific Antibody Monitoring and the Role of Kidney Biopsy in Simultaneous Liver and Kidney Recipients With De Novo Donor-specific Antibodies. Transplantation 2021;105:1548-55. [PMID: 32732618 DOI: 10.1097/TP.0000000000003399] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
89 Weniger M, Andrassy J, Weig T, Grabein B, Crispin A, Rentsch M, Siebers C, Bazhin A, D'haese JG, Hartwig W, Werner J, Guba M, Faist E, Pratschke S, Angele MK. Temporary Intra-Operative Portocaval Shunts, Post-Operative Infections, and Mid-Term Survival after Cava-Sparing Liver Transplantation. Surgical Infections 2017;18:803-9. [DOI: 10.1089/sur.2017.036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
90 Schiano TD, Florman S, Fiel MI. Recurrent Idiopathic Liver Allograft Failure. Am J Clin Pathol 2019;152:369-76. [PMID: 31139817 DOI: 10.1093/ajcp/aqz044] [Reference Citation Analysis]
91 Touzot M, Couvrat-Desvergnes G, Castagnet S, Cesbron A, Renaudin K, Cantarovich D, Giral M. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection. Transplantation. 2015;99:63-68. [PMID: 25029384 DOI: 10.1097/tp.0000000000000285] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
92 Grabhorn E, Binder TM, Obrecht D, Brinkert F, Lehnhardt A, Herden U, Peine S, Nashan B, Ganschow R, Briem-Richter A. Long-term Clinical Relevance of De Novo Donor-Specific Antibodies After Pediatric Liver Transplantation. Transplantation. 2015;99:1876-1881. [PMID: 25706279 DOI: 10.1097/tp.0000000000000638] [Cited by in Crossref: 44] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
93 Vandevoorde K, Ducreux S, Bosch A, Guillaud O, Hervieu V, Chambon-Augoyard C, Poinsot D, André P, Scoazec JY, Robinson P, Boillot O, Dubois V, Dumortier J. Prevalence, Risk Factors, and Impact of Donor-Specific Alloantibodies After Adult Liver Transplantation. Liver Transpl 2018;24:1091-100. [PMID: 29665189 DOI: 10.1002/lt.25177] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
94 Barten MJ, Schulz U, Beiras-Fernandez A, Berchtold-Herz M, Boeken U, Garbade J, Hirt S, Richter M, Ruhpawar A, Sandhaus T, Schmitto JD, Schönrath F, Schramm R, Schweiger M, Wilhelm M, Zuckermann A. The clinical impact of donor-specific antibodies in heart transplantation. Transplant Rev (Orlando) 2018;32:207-17. [PMID: 29804793 DOI: 10.1016/j.trre.2018.05.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
95 O'Leary JG, Cai J, Freeman R, Banuelos N, Hart B, Johnson M, Jennings LW, Kaneku H, Terasaki PI, Klintmalm GB. Proposed Diagnostic Criteria for Chronic Antibody-Mediated Rejection in Liver Allografts. Am J Transplant. 2016;16:603-614. [PMID: 26469278 DOI: 10.1111/ajt.13476] [Cited by in Crossref: 64] [Cited by in F6Publishing: 47] [Article Influence: 9.1] [Reference Citation Analysis]
96 Pascual J, Zuckermann A, Djamali A, Hertig A, Naesens M. Rabbit antithymocyte globulin and donor-specific antibodies in kidney transplantation — A review. Transplantation Reviews 2016;30:85-91. [DOI: 10.1016/j.trre.2015.12.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
97 Cuadrado A, San Segundo D, López-Hoyos M, Crespo J, Fábrega E. Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation. World J Gastroenterol 2015; 21(39): 11016-11026 [PMID: 26494958 DOI: 10.3748/wjg.v21.i39.11016] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
98 Burballa C, Pérez-Saéz MJ, Redondo-Pachón D, García C, Mir M, Arias-Cabrales C, Valenzuela NM, Reed EF, Pascual J, Crespo M. Luminex screening first vs. direct single antigen bead assays: Different strategies for HLA antibody monitoring after kidney transplantation. Hum Immunol 2020;81:293-9. [PMID: 32279925 DOI: 10.1016/j.humimm.2020.03.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
99 Kaneku H, Wozniak LJ. Donor-specific human leukocyte antigen antibodies in intestinal transplantation. Curr Opin Organ Transplant. 2014;19:261-266. [PMID: 24811437 DOI: 10.1097/mot.0000000000000078] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
100 Arias M, Serón D, Herrero I, Rush DN, Wiebe C, Nickerson PW, Ussetti P, Rodrigo E, de Cos M. Subclinical Antibody-Mediated Rejection. Transplantation 2017;101:S1-S18. [DOI: 10.1097/tp.0000000000001735] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Höfer A, Jonigk D, Hartleben B, Verboom M, Hallensleben M, Hübscher SG, Manns MP, Jaeckel E, Taubert R. DSA Are Associated With More Graft Injury, More Fibrosis, and Upregulation of Rejection-associated Transcripts in Subclinical Rejection. Transplantation 2020;104:551-61. [PMID: 31651790 DOI: 10.1097/TP.0000000000003034] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
102 Aday AW, O'Leary JG. Donor-Specific Antibodies' Meaningful Impact on Liver Transplantation. Liver Transpl 2018;24:999-1000. [PMID: 30028076 DOI: 10.1002/lt.25299] [Reference Citation Analysis]
103 O'Leary JG, Kaneku H, Jennings LW, Bañuelos N, Susskind BM, Terasaki PI, Klintmalm GB. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl 2013;19:973-80. [PMID: 23780820 DOI: 10.1002/lt.23687] [Cited by in Crossref: 92] [Cited by in F6Publishing: 79] [Article Influence: 10.2] [Reference Citation Analysis]
104 Kivelä JM, Kosola S, Peräsaari J, Mäkisalo H, Jalanko H, Holmberg C, Pakarinen MP, Lauronen J. Donor-specific antibodies after pediatric liver transplantation: a cross-sectional study of 50 patients. Transpl Int 2016;29:494-505. [PMID: 26806435 DOI: 10.1111/tri.12747] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
105 Neuberger JM, Bechstein WO, Kuypers DR, Burra P, Citterio F, De Geest S, Duvoux C, Jardine AG, Kamar N, Krämer BK, Metselaar HJ, Nevens F, Pirenne J, Rodríguez-Perálvarez ML, Samuel D, Schneeberger S, Serón D, Trunečka P, Tisone G, van Gelder T. Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group. Transplantation 2017;101:S1-S56. [PMID: 28328734 DOI: 10.1097/TP.0000000000001651] [Cited by in Crossref: 114] [Cited by in F6Publishing: 43] [Article Influence: 22.8] [Reference Citation Analysis]
106 Aziz F, Mandelbrot D, Parajuli S, Al-Qaoud T, Redfield R, Kaufman D, Odorico JS. Alloimmunity in pancreas transplantation. Curr Opin Organ Transplant 2020;25:322-8. [PMID: 32692039 DOI: 10.1097/MOT.0000000000000776] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
107 Dumortier J, Dedic T, Erard-poinsot D, Rivet C, Guillaud O, Chambon-augoyard C, Bosch A, Lachaux A, Couchonnal E, Thaunat O, Boillot O, Dubois V. Pregnancy and donor-specific HLA-antibody-mediated rejection after liver transplantation: “Liaisons dangereuses”? Transplant Immunology 2019;54:47-51. [DOI: 10.1016/j.trim.2019.02.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
108 Parekh R, Kazimi M, Skorupski S, Fagoaga O, Jafri S, Segovia MC. Intestine Transplantation Across a Positive Crossmatch With Preformed Donor-Specific Antibodies. Transplant Proc 2016;48:489-91. [PMID: 27109984 DOI: 10.1016/j.transproceed.2015.10.084] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
109 Nakano R, Ohira M, Ishiyama K, Ide K, Kobayashi T, Tahara H, Shimizu S, Arihiro K, Imamura M, Chayama K, Tanaka Y, Ohdan H. Acute Graft Rejection and Formation of De Novo Donor-Specific Antibodies Triggered by Low Cyclosporine Levels and Interferon Therapy for Recurrent Hepatitis C Infection After Liver Transplantation: A Case Report. Transplant Proc 2017;49:1634-8. [PMID: 28838454 DOI: 10.1016/j.transproceed.2017.05.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
110 Wadström J, Ericzon BG, Halloran PF, Bechstein WO, Opelz G, Serón D, Grinyó J, Loupy A, Kuypers D, Mariat C, Clancy M, Jardine AG, Guirado L, Fellström B, O'Grady J, Pirenne J, O'Leary JG, Aluvihare V, Trunečka P, Baccarani U, Neuberger J, Soto-Gutierrez A, Geissler EK, Metzger M, Gray M. Advancing Transplantation: New Questions, New Possibilities in Kidney and Liver Transplantation. Transplantation 2017;101 Suppl 2S:S1-S41. [PMID: 28125449 DOI: 10.1097/TP.0000000000001563] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.8] [Reference Citation Analysis]
111 Wozniak LJ, Hickey MJ, Chan AP, Venick RS, Farmer DG, Busuttil RW, Reed EF, McDiarmid SV. Angiotensin II Type-1 Receptor Antibodies Are Associated With Active Allograft Dysfunction Following Pediatric Liver Transplantation. Transplantation 2020;104:2547-56. [PMID: 32101982 DOI: 10.1097/TP.0000000000003206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
112 Ono K, Ide K, Tanaka Y, Ohira M, Tahara H, Tanimine N, Yamane H, Ohdan H. Molecular Mismatch Predicts T Cell-Mediated Rejection and De Novo Donor-Specific Antibody Formation After Living Donor Liver Transplantation. Liver Transpl 2021. [PMID: 34310028 DOI: 10.1002/lt.26238] [Reference Citation Analysis]
113 Demetris AJ, Bellamy C, Hübscher SG, O’Leary J, Randhawa PS, Feng S, Neil D, Colvin RB, McCaughan G, Fung JJ. 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. Am J Transplant. 2016; Epub ahead of print. [PMID: 27273869 DOI: 10.1111/ajt.13909] [Cited by in Crossref: 230] [Cited by in F6Publishing: 187] [Article Influence: 38.3] [Reference Citation Analysis]
114 Fujiyama N, Satoh S, Saito M, Numakura K, Inoue T, Yamamoto R, Saito T, Nara T, Kanda S, Narita S, Kagaya H, Miura M, Habuchi T. Association of immunosuppressive agents and cytomegalovirus infection with de novo donor-specific antibody development within 1 year after renal transplantation. Int Immunopharmacol 2019;76:105881. [PMID: 31520989 DOI: 10.1016/j.intimp.2019.105881] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
115 Egawa H, Sakisaka S, Teramukai S, Sakabayashi S, Yamamoto M, Umeshita K, Uemoto S. Long-Term Outcomes of Living-Donor Liver Transplantation for Primary Biliary Cirrhosis: A Japanese Multicenter Study. Am J Transplant. 2016;16:1248-1257. [PMID: 26731039 DOI: 10.1111/ajt.13583] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
116 Kovandova B, Slavcev A, Honsova E, Erhartova D, Skibova J, Viklicky O, Trunecka P. De novo HLA Class II antibodies are associated with the development of chronic but not acute antibody-mediated rejection after liver transplantation - a retrospective study. Transpl Int 2020;33:1799-806. [PMID: 33020979 DOI: 10.1111/tri.13763] [Reference Citation Analysis]